• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Vasoactive intestinal polypeptide receptor 2 (VIPR2), Truncated

ACP07039

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP07039 Target NameVIPR2
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Protein LengthPartialPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDP41587
Background Information
  • Uniprot Id

    P41587

  • Target Species

    Human

  • Target Name

    VIPR2

  • Target Full Name

    Vasoactive intestinal polypeptide receptor 2

  • Target Function

    This is a receptor for VIP as well as PACAP-38 and -27, the activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Can be coupled to phospholipase C.

  • Target Subcellular Location

    Cell membrane; Multi-pass membrane protein.

  • Target Protein Families

    G-protein coupled receptor 2 family

  • Target Tissue Specificity

    Expressed in CD4+ T-cells, but not in CD8+ T-cells. Expressed in the T-cell lines Jurkat, Peer, MOLT-4, HSB, YT and SUP-T1, but not in the T-cell lines HARRIS and HuT 78.

  • Target Synonyms

    VIPR2; VIP2R; Vasoactive intestinal polypeptide receptor 2; VIP-R-2; Helodermin-preferring VIP receptor; Pituitary adenylate cyclase-activating polypeptide type III receptor; PACAP type III receptor; PACAP-R-3; PACAP-R3; VPAC2

Inquire Recombinant Human Vasoactive intestinal polypeptide receptor 2 (VIPR2), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification